Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study

Documenti analoghi

• Proton Pump Inhibitor Use Exceeding the U.S. Food and Drug Administration Approved Treatment Duration for Patients With Peptic Ulcer Disease: A Retrospective Cohort Study
  di: Jordan A. Villars, et al.
  Pubblicazione: (2025)
• Real‐World Evidence of Indapamide‐Induced Rhabdomyolysis: A Retrospective Analysis of Electronic Health Records
  di: Raseel Alroba, et al.
  Pubblicazione: (2024)
• The Risk of Hypothyroidism With the Use of GLP ‐1 Receptor Agonists in Saudi Arabia
  di: Almaha Alfakhri, et al.
  Pubblicazione: (2026)
• Clarithromycin Versus Azithromycin for Community‐Acquired Pneumonia and the Risk of Major Adverse Cardiovascular Events: A Multicentre Cohort Study Using Data From Canada and Denmark
  di: Theis Skovsgaard Itenov, et al.
  Pubblicazione: (2025)
• Risk of Ischaemic Stroke Varies With Antithrombotic Drugs Use in Proton Pump Inhibitor Users: A Self‐Controlled Case Series Study
  di: Min Fan, et al.
  Pubblicazione: (2025)